Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Clinical trial NCT04150965 · TERMINATED
Trial details
- NCT number
- NCT04150965
- Sponsor
- Multiple Myeloma Research Consortium
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-10
- Primary completion
- 2024-08-30
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.